Company Overview
LIVIN operates as a niche healthy-lifestyle retailer across Lithuania, Latvia and Estonia, selling supplements, organic foods, fitness equipment and wellness accessories. With revenue below €10 m it remains a small-scale player relative to listed Baltic peers, yet benefits from secular demand for health products in a region where organised retail penetration is still rising.
Deal Context
BGF’s sale of its controlling stake to Ogmios Group constitutes a classic PE exit to a local strategic buyer. Ogmios gains immediate Baltic scale, store network and supplier relationships, while the transaction signals that health-retail assets can attract domestic capital even at modest absolute sizes. No founder succession or acqui-hire elements are evident; the deal is purely strategic consolidation.
Valuation Context
Listed Baltic multiples range from 5.6–6.1× EV/EBITDA for low-margin retailers (Grigeo, Pieno Zvaigzdes) to 8.5–15.1× for higher-quality consumer names (APG, TKM). A sub-€10 m private company would trade at a 30–40 % liquidity and size discount, implying 4.0–5.5× EBITDA or 0.6–0.9× revenue assuming typical 12–15 % margins. Revenue multiples are the more relevant metric given limited public EBITDA disclosure for micro-retailers.
Triage Verdict
REVIEW
- Fit: Exact sector and geography match with announced transaction; growth tailwinds intact.
- Red flags: Revenue scale below €10 m limits liquidity and increases key-man exposure.
- Next step: Request three-year financials and customer-concentration schedule from Ogmios or BaltCap to model synergy-driven upside.
Key Risk
Sustained weakness in Baltic discretionary spending could compress margins faster than peers, pushing the asset toward the lower end of the 5–6× EBITDA range.
Bottom line: Concrete exit provides a valuation anchor, but size and cyclical exposure warrant further diligence before committing.
| # | Fund | AUM | YTD | Positions |
|---|---|---|---|---|
| 1 | Ma Investment Partnership, LP | $322.6B | +177.4% | 18 |
| 2 | Graticule Asia Macro Advisors LLC | $1.1T | +169.2% | 4 |
| 3 | Shengqi Capital (Hong Kong) Ltd | $95.6B | +147.9% | 10 |
| 4 | Anther Capital Ltd | $3.8T | +147.8% | 31 |
| 5 | Central Asset Investments & Manag… | $261.4B | +134.4% | 63 |
| 6 | Oxbow Capital Management (HK) Ltd | $731.4B | +130.1% | 14 |
| 7 | Merck & Co., Inc. | $625.7B | +120.1% | 26 |
| 8 | Elemental Capital Partners LLC | $422.8B | +117.1% | 18 |
| 9 | Step Capital Management Pte. Ltd. | $467.4B | +112.1% | 53 |
| 10 | AIHC Capital Management Ltd | $226.4B | +111.3% | 11 |
| Security | Value | Weight |
|---|---|---|
| MICRON TECHNOLOGY INC | $54.9B | 25.8% |
| MICRON TECHNOLOGY INC | $54.2B | 25.4% |
| ADVANCED MICRO DEVICES INC | $39.2B | 18.4% |
| MODERNA INC | $32.8B | 15.4% |
| ADVANCED MICRO DEVICES INC | $32.1B | 15.1% |
| Company | Ticker | Exchange | Expected | Deal Value |
|---|---|---|---|---|
| SpaceX | SPCX | NASDAQ | 2026-06-12 | — |
| Pelican Acquisition II Corp | PLCIU | UNKNOWN | TBD | $86.2M |
| Cartesian Growth Corp IV | CGCFU | UNKNOWN | TBD | $287.5M |
| Research Alliance Corp IV | RACD | UNKNOWN | TBD | $75.0M |
| GLGHK Ltd | GLG | UNKNOWN | TBD | $40.2M |
| Company | Sector | Valuation |
|---|---|---|
| Anthropic | Artificial Intelligence | $965.0B |
| OpenAI | Artificial Intelligence | $894.3B |
| Databricks | Data and Analytics | $193.3B |
# Integration & 100-Day Planner You build a post-close integration plan with day-one actions, 30-60-90 day milestones, and a 100-day value-creation roadmap. ## Workstreams (standard) 1. **Leadership & governance** — CEO transition, board, reporting lines 2. **Comms** — internal (employees), external (customers, suppliers, regulators) 3. **Finance** — close process, financial reporting, treasury, banking 4. **HR** — benefits, comp, retention, policies 5. **IT & systems** — access, email, security, ERP 6. **Commercial** — customer retention, pricing, pipeline handover 7. **Operations** — supp…